Repurposing pentamidine using hyaluronic acid-based nanocarriers for skeletal muscle treatment in myotonic dystrophy
Copyright © 2022 Elsevier Inc. All rights reserved..
In a context of drug repurposing, pentamidine (PTM), an FDA-approved antiparasitic drug, has been proposed to reverse the splicing defects associated in myotonic dystrophy type 1 (DM1). However, clinical use of PTM is hinder by substantial toxicity, leading to find alternative delivery strategies. In this work we proposed hyaluronic acid-based nanoparticles as a novel encapsulation strategy to efficiently deliver PTM to skeletal muscles cells. In vitro studies on C2C12 myoblasts and myotubes showed an efficient nanoparticles' internalization with minimal toxicity. More interestingly, our findings evidenced for the first time the endosomal escape of hyaluronic acid-based nanocarriers. Ex vivo studies showed an efficient nanoparticles' internalization within skeletal muscle fibers. Finally, the therapeutic efficacy of PTM-loaded nanosystems to reduce the number of nuclear foci has been demonstrated in a novel DM1 in vitro model. So far, current data demonstrated the potency of hyaluronic acid-based nanosystems as efficient nanocarrier for delivering PTM into skeletal muscle and mitigate DM1 pathology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Nanomedicine : nanotechnology, biology, and medicine - 47(2023) vom: 01. Jan., Seite 102623 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Repellin, Mathieu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
673LC5J4LQ |
|---|
| Anmerkungen: |
Date Completed 15.12.2022 Date Revised 20.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.nano.2022.102623 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348234627 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348234627 | ||
| 003 | DE-627 | ||
| 005 | 20231226035711.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nano.2022.102623 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1160.xml |
| 035 | |a (DE-627)NLM348234627 | ||
| 035 | |a (NLM)36309185 | ||
| 035 | |a (PII)S1549-9634(22)00109-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Repellin, Mathieu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repurposing pentamidine using hyaluronic acid-based nanocarriers for skeletal muscle treatment in myotonic dystrophy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2022 | ||
| 500 | |a Date Revised 20.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a In a context of drug repurposing, pentamidine (PTM), an FDA-approved antiparasitic drug, has been proposed to reverse the splicing defects associated in myotonic dystrophy type 1 (DM1). However, clinical use of PTM is hinder by substantial toxicity, leading to find alternative delivery strategies. In this work we proposed hyaluronic acid-based nanoparticles as a novel encapsulation strategy to efficiently deliver PTM to skeletal muscles cells. In vitro studies on C2C12 myoblasts and myotubes showed an efficient nanoparticles' internalization with minimal toxicity. More interestingly, our findings evidenced for the first time the endosomal escape of hyaluronic acid-based nanocarriers. Ex vivo studies showed an efficient nanoparticles' internalization within skeletal muscle fibers. Finally, the therapeutic efficacy of PTM-loaded nanosystems to reduce the number of nuclear foci has been demonstrated in a novel DM1 in vitro model. So far, current data demonstrated the potency of hyaluronic acid-based nanosystems as efficient nanocarrier for delivering PTM into skeletal muscle and mitigate DM1 pathology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Biomaterials | |
| 650 | 4 | |a C2C12 cells | |
| 650 | 4 | |a DM1 cell model | |
| 650 | 4 | |a Muscular dystrophies | |
| 650 | 4 | |a Nanoparticles | |
| 650 | 7 | |a Pentamidine |2 NLM | |
| 650 | 7 | |a 673LC5J4LQ |2 NLM | |
| 650 | 7 | |a Hyaluronic Acid |2 NLM | |
| 650 | 7 | |a 9004-61-9 |2 NLM | |
| 700 | 1 | |a Carton, Flavia |e verfasserin |4 aut | |
| 700 | 1 | |a Boschi, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Galiè, Mirco |e verfasserin |4 aut | |
| 700 | 1 | |a Perduca, Massimiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Calderan, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Jacquier, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Carras, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Schaeffer, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Briançon, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Lollo, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Malatesta, Manuela |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine : nanotechnology, biology, and medicine |d 2005 |g 47(2023) vom: 01. Jan., Seite 102623 |w (DE-627)NLM16062021X |x 1549-9642 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2023 |g day:01 |g month:01 |g pages:102623 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nano.2022.102623 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2023 |b 01 |c 01 |h 102623 | ||